AUG 16, 2018 08:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Advancing precision immunotherapy through next-generation sequencing of T cell receptors: Part I

SPONSORED BY: Thermo Fisher Scientific Ion Torrent
4 8 2013

  • Staff Scientist, Bioinformatics, Thermo Fisher Scientific
      Dr. Looney is an accomplished computational biologist and immunologist with expertise in methods and applications of B and T cell receptor sequencing, including biomarker discovery and assay development. He is currently a Staff Scientist and Informatics Lead for Immune Repertoire Sequencing within the Clinical Sequencing Division at Thermo Fisher Scientific. Dr. Looney's interests and specialties are centered around repertoire analysis for immuno-oncology, autoimmunity and infectious disease translational research.

    DATE: August 16, 2018
    TIME: 08:00AM PDT
    Immuno-Oncology Webinar Series (#2 of 3)
    This webinar will review recent advancements in the application of next-generation sequencing of T cell receptor beta (TCRB) chain repertoires towards predictive and mechanistic biomarker discovery for cancer immunotherapy. Dr. Looney will focus on immunotherapy biomarker applications of a long-amplicon TCRB sequencing assay which provides coverage of the CDR1, 2 and 3 regions of the rearranged TCRB chain. He will highlight recent data from individuals receiving checkpoint blockade immunotherapy for cancer which suggest that long-amplicon TCRB repertoire sequencing of pre-treatment peripheral blood may be used to identify predictive biomarkers for immune-mediated adverse events and objective clinical response.
    Learning Objectives:
    • Understand current applications of T cell receptor sequencing to immunotherapy translational research.
    • Describe the advantages of long-amplicon TCRB sequencing via Ion Torrent for immunotherapy biomarker discovery from peripheral blood.
    Register for our 3 Part Series here:

    Show Resources
    Loading Comments...